Source: Sharecast
AstraZeneca said that when used in conjunction with pertuzumab, Enhertu had demonstrated a "highly statistically significant and clinically meaningful improvement" in progression-free survival versus taxane, trastuzumab and pertuzumab as a first-line therapy for patients with HER2-positive metastatic breast cancer.
The FTSE 100-listed group stated the improvement in progression-free survival was seen across all pre-specified patient subgroups with Enhertu in combination with pertuzumab. However, it noted that its key secondary endpoint of overall survival "was not mature at the time of this planned interim analysis" but said interim data pointed to "an early trend" favouring the Enhertu combination compared with THP.
AstraZeneca's Susan Galbraith said: "This is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic breast cancer patient population compared to the current 1st-line standard of care. This is a significant milestone for patients and sets the foundation for Enhertu in combination with pertuzumab as an important treatment option in the first-line HER2-positive setting."
As of 0855 BST, AstraZeneca shares were down 0.18% at 10,106.00p.
Reporting by Iain Gilbert at Sharecast.com